Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biotech Backers Learn To Live With Exit-By-Earn-Out

This article was originally published in The Pink Sheet Daily

Executive Summary

Even as both public investors and pharma companies more vigorously sniff out biopharma opportunities, exits for venture-backed firms remain scarce. Can risk-sharing acquisitions save the day?

You may also be interested in...



Clovis Oncology Seeks $149.5 Million IPO

The Colorado cancer drug maker is seeking financing through the public capital markets.

Clovis Oncology Seeks $149.5 Million IPO

The Colorado cancer drug maker is seeking financing through the public capital markets.

Emergent BioSolutions Takes Out Troubled Trubion For $97 Million

Known for its biodefense work, Emergent used cash from its anthrax vaccine contracts to scoop up a developer of antibody-like therapies for autoimmune and cancer indications.

Related Content

Topics

UsernamePublicRestriction

Register

PS070587

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel